Human Genome and Medtronic Shares Receive New Analyst Price Targets
Wall St. Watchdog reveals information about companies for which stock analysts reiterated ratings in the Healthcare sector for the week ending November 25th, 2011.
- Human Genome (NASDAQ:HGSI): Stifel Nicolaus reiterated its rating of Buy for this company and changed its price target from $17 to $15 on Nov 22nd. The shares recently traded at $7.34, down $0.15, or 2% since the analyst’s rating. About the company: Human Genome Sciences, Inc. researches and develops proprietary pharmaceutical and diagnostic products. The Company’s products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes. Get the most recent company news and stock data here >>
- Medtronic (NYSE:MDT): Brean Murray reiterated its rating of Buy for this company and changed its price target from $44 to $42 on Nov 23rd. The shares recently traded at $34.76, up $0.81, or 2.39% since the analyst’s rating. About the company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide. Get the most recent company news and stock data here >>
(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)
Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>